BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 26153859)

  • 21. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.
    Wortham NC; Ahamed E; Nicol SM; Thomas RS; Periyasamy M; Jiang J; Ochocka AM; Shousha S; Huson L; Bray SE; Coombes RC; Ali S; Fuller-Pace FV
    Oncogene; 2009 Nov; 28(46):4053-64. PubMed ID: 19718048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.
    Nakles RE; Shiffert MT; Díaz-Cruz ES; Cabrera MC; Alotaiby M; Miermont AM; Riegel AT; Furth PA
    Mol Endocrinol; 2011 Apr; 25(4):549-63. PubMed ID: 21292825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
    Liang J; Ingalla ER; Yao X; Wang BE; Tai L; Giltnane J; Liang Y; Daemen A; Moore HM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Tam L; Bacarro N; Roose-Girma M; Bellet M; Hafner M; Metcalfe C
    Sci Transl Med; 2022 Sep; 14(663):eabo5959. PubMed ID: 36130016
    [No Abstract]   [Full Text] [Related]  

  • 25. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
    Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
    Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
    PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor.
    Moore NL; Hanson AR; Ebrahimie E; Hickey TE; Tilley WD
    J Steroid Biochem Mol Biol; 2020 May; 199():105548. PubMed ID: 31805393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts.
    Bouclier C; Marsaud V; Bawa O; Nicolas V; Moine L; Opolon P; Renoir JM
    Breast Cancer Res Treat; 2010 Jul; 122(1):145-58. PubMed ID: 19771505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site.
    Petz LN; Ziegler YS; Schultz JR; Nardulli AM
    Mol Endocrinol; 2004 Mar; 18(3):521-32. PubMed ID: 14684847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
    Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
    Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer.
    Lou P; Li C; Shi L; Xia TS; Zhou W; Wu J; Zhou X; Li X; Wang Y; Wei JF; Ding Q
    Oncotarget; 2017 Mar; 8(10):16387-16400. PubMed ID: 27634883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
    Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
    Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.
    Esber N; Cherbonnier C; Resche-Rigon M; Hamze A; Alami M; Fagart J; Loosfelt H; Lombès M; Chabbert-Buffet N
    Horm Cancer; 2016 Apr; 7(2):137-47. PubMed ID: 26941094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-range transcriptional control of progesterone receptor gene expression.
    Bonéy-Montoya J; Ziegler YS; Curtis CD; Montoya JA; Nardulli AM
    Mol Endocrinol; 2010 Feb; 24(2):346-58. PubMed ID: 19952285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells.
    Stender JD; Stossi F; Funk CC; Charn TH; Barnett DH; Katzenellenbogen BS
    Mol Endocrinol; 2011 Oct; 25(10):1699-709. PubMed ID: 21868451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.
    Meeran SM; Patel SN; Li Y; Shukla S; Tollefsbol TO
    PLoS One; 2012; 7(5):e37748. PubMed ID: 22662208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
    Lu W; Katzenellenbogen BS
    Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells.
    Velarde MC; Zeng Z; McQuown JR; Simmen FA; Simmen RC
    Mol Endocrinol; 2007 Dec; 21(12):2988-3001. PubMed ID: 17717078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.